Corporate Responsibility at MSD:

Finding New Ways to Create a Healthier and More Sustainable World

Brenda Colatrella
associate vice president, Corporate Responsibility

Operating responsibly is not only fundamental to MSD’s long-term success as a global biopharmaceutical company, it is also increasingly important to our stakeholders as expectations for how companies conduct themselves and contribute to society continue to rise.

How do we at MSD define corporate responsibility?

For MSD, our approach to corporate responsibility is about the health, economic, social and environmental impact we have on individuals and communities around the world. We hold ourselves accountable to our many stakeholders, including patients, employees, customers and shareholders, whose perspectives help to define our corporate responsibility priorities

Each year, we set a high bar for our performance when it comes to increasing access to our medicines and vaccines, protecting the environment, promoting a positive, diverse and inclusive workplace for our employees, and conducting business in an ethical and transparent manner.

In addition to responding to the needs of stakeholders, our corporate responsibility efforts also support the United Nations’ Sustainable Development Goals(SDGs), the international community’s aspirations for improving the lives of the world’s poorest people by 2030. We have joined global leaders to address the goals on health and well-being, clean water, climate change, diversity and inclusion, responsible consumption and production and others. Our support of the SDGs is a testament to our company’s 125-year legacy of inventing for life to create a healthier world for all.

Below are a few highlights from our recently released corporate responsibility report that highlight our commitment to advance the social and economic conditions in the communities where we work and live:

2017/2018 Corporate Responsibility Report Highlights:

  • We have expanded the MECTIZAN® Donation Program to reach up to 100 million more people per year through 2025 as part of the global effort to eliminate lymphatic filariasis.
  • Through MSD for Mothers, our 10-year, $500 million global initiative to end preventable maternal deaths, we have improved access to quality maternal healthcare and modern contraception for more than 6 million women around the world.
  • In 2017, we achieved a 31-percent increase of spend with diverse suppliers, after a 57-percent increase in 2016, exceeding our corporate goal to achieve $1.2 billion in spend with minority-owned, women-owned, veteran-owned, LGBT-owned and disability-owned business enterprises.
  • We progressed toward our 2025 goal of having more than 50 percent of our purchased electricity come from renewable sources by signing a virtual power purchase agreement (VPPA) with Invenergy.

We are also proud to have been named to TIME magazine’s inaugural list of the Most Genius Companies of 2018 and Fortune Magazine’s Change the World list for our work in the fight against Ebola.

We are driven by our dedication to you—our customers, our employees, our partners and shareholders—to find new ways to discover, develop and deliver innovative medicines and vaccines for a healthier world, while preserving the planet on which we all live, creating an inclusive workplace and conducting our business in an ethical and transparent manner. We will continue to build on our 125+year legacy of inventing for life to create a healthier and more sustainable world for all.

I encourage you to visit to read our 2017/2018 Corporate Responsibility Report.